Anti-mycobacterial compounds derived from marine organisms: Mode of actions and potential in tuberculosis treatment

A. S. Babu, K. V. Rao
{"title":"Anti-mycobacterial compounds derived from marine organisms: Mode of actions and potential in tuberculosis treatment","authors":"A. S. Babu, K. V. Rao","doi":"10.35118/APJMBB.2021.029.2.03","DOIUrl":null,"url":null,"abstract":"Mycobacteria are an extremely large group of bacteria that are normal inhabitants of soil and water. It has an exceptional propensity to adjust to varying environmental conditions which has led to the success of this pathogen. Mycobacterium tuberculosis can inhabit human tissues for years without replicating, thereby resuming growth and resulting in active tuberculosis with an increased latency period compared to any other deadly disease. The existing vaccines and drugs in the market to treat tuberculosis are ineffective and pose severe side effects. Hence, the development of a novel drug with high efficacy to kill these replicating and non-replicating bacilli appears to be an attractive solution to tackle this problem. The extraction of novel biologically active compounds from marine organisms has prospective biomedical applications for future drug discovery. Tuberculosis treatment, in specific, may benefit from the identification of novel and efficient marine-based compounds. A few anti-mycobacterial compounds belonging to the class alkaloids, terpenoids, peptides, and steroids have been isolated from marine organisms and are known to have potential activity against mycobacteria. This review focuses on the currently available anti-mycobacterial compounds and quorum sensing inhibitors of marine origin along with their mode of action and their significant potential in the treatment of mycobacteria associated strains.","PeriodicalId":8566,"journal":{"name":"Asia-pacific Journal of Molecular Biology and Biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia-pacific Journal of Molecular Biology and Biotechnology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35118/APJMBB.2021.029.2.03","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Mycobacteria are an extremely large group of bacteria that are normal inhabitants of soil and water. It has an exceptional propensity to adjust to varying environmental conditions which has led to the success of this pathogen. Mycobacterium tuberculosis can inhabit human tissues for years without replicating, thereby resuming growth and resulting in active tuberculosis with an increased latency period compared to any other deadly disease. The existing vaccines and drugs in the market to treat tuberculosis are ineffective and pose severe side effects. Hence, the development of a novel drug with high efficacy to kill these replicating and non-replicating bacilli appears to be an attractive solution to tackle this problem. The extraction of novel biologically active compounds from marine organisms has prospective biomedical applications for future drug discovery. Tuberculosis treatment, in specific, may benefit from the identification of novel and efficient marine-based compounds. A few anti-mycobacterial compounds belonging to the class alkaloids, terpenoids, peptides, and steroids have been isolated from marine organisms and are known to have potential activity against mycobacteria. This review focuses on the currently available anti-mycobacterial compounds and quorum sensing inhibitors of marine origin along with their mode of action and their significant potential in the treatment of mycobacteria associated strains.
从海洋生物中提取的抗分枝杆菌化合物:作用方式和结核病治疗的潜力
分枝杆菌是一种非常大的细菌群,是土壤和水中的正常居民。它有一种特殊的倾向来适应不同的环境条件,这导致了这种病原体的成功。结核分枝杆菌可以在人体组织中存活数年而不复制,从而恢复生长,导致活动性结核病,与任何其他致命疾病相比,潜伏期更长。市场上现有的治疗结核病的疫苗和药物是无效的,而且有严重的副作用。因此,开发一种高效的新药来杀死这些复制和非复制杆菌似乎是解决这一问题的一个有吸引力的解决方案。从海洋生物中提取新的生物活性化合物对未来的药物开发具有广阔的生物医学应用前景。具体地说,结核病的治疗可能受益于鉴定新的和有效的海洋化合物。一些抗分枝杆菌化合物属于生物碱类、萜类、多肽类和类固醇类,已经从海洋生物中分离出来,并且已知对分枝杆菌具有潜在的活性。本文综述了目前可用的海洋来源的抗分枝杆菌化合物和群体感应抑制剂,以及它们的作用方式和它们在治疗分枝杆菌相关菌株方面的巨大潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Asia-pacific Journal of Molecular Biology and Biotechnology
Asia-pacific Journal of Molecular Biology and Biotechnology Biochemistry, Genetics and Molecular Biology-Biotechnology
CiteScore
0.90
自引率
0.00%
发文量
25
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信